|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0013089,
umls-concept:C0020823,
umls-concept:C0029463,
umls-concept:C0205131,
umls-concept:C0205225,
umls-concept:C0239307,
umls-concept:C0278512,
umls-concept:C0282460,
umls-concept:C0521324,
umls-concept:C2810863
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1999-12-22
|
|
pubmed:abstractText |
Despite advances in the treatment of primary limb osteosarcoma, the outcome of patients with primary metastatic and axial skeletal disease remains poor. The European Osteosarcoma Intergroup have assessed a combination chemotherapy regimen consisting of ifosfamide (IFOS) 3 g/m2/dl-2, doxorubicin (DOX) 25 mg/m2/dl-3 i.v. bolus and cisplatin (CDDP) 100 mg/m2/dl.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:Cortés-FunesHH,
pubmed-author:HogendoornP CPC,
pubmed-author:KirkpatrickAA,
pubmed-author:MachinDD,
pubmed-author:NooijMM,
pubmed-author:PringleJJ,
pubmed-author:SomersRR,
pubmed-author:SouhamiR LRL,
pubmed-author:UscinskaB MBM,
pubmed-author:VoûteP APA,
pubmed-author:WeedenSS,
pubmed-author:van GlabbekeMM,
pubmed-author:van der EijkenJ WJW
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1211-8
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:10586339-Adolescent,
pubmed-meshheading:10586339-Adult,
pubmed-meshheading:10586339-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10586339-Child,
pubmed-meshheading:10586339-Cisplatin,
pubmed-meshheading:10586339-Combined Modality Therapy,
pubmed-meshheading:10586339-Doxorubicin,
pubmed-meshheading:10586339-Female,
pubmed-meshheading:10586339-Humans,
pubmed-meshheading:10586339-Ifosfamide,
pubmed-meshheading:10586339-Male,
pubmed-meshheading:10586339-Osteosarcoma,
pubmed-meshheading:10586339-Prognosis,
pubmed-meshheading:10586339-Survival Analysis
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI).
|
|
pubmed:affiliation |
Emma Kinderziekenhuis, Academic Medical Center, Amsterdam, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
